Business Wire

GROUPE-RSL

Share
Canadian Company Groupe RSL Produces Canada’s First Lab-Grown Diamond Gem

Groupe RSL is the first company to produce a Canadian lab-grown diamond gem, at its production facility in Quebec. The company is currently producing large diamonds for the premium jewellery market. With sustainability at the heart of its approach, Groupe RSL believes that lab diamonds have the potential to significantly reduce the environmental impacts of diamond production.

“Laboratory diamonds have the potential to revolutionize the industry, while reducing the environmental and human costs associated with diamond production,” said Luke Sinclair, CFO of Groupe RSL. “Consumers are seeking greater transparency in the diamonds that they purchase, and we firmly believe that the industry need not be at odds with the environment or principles of social responsibility. We are excited to see how the lab-grown diamond industry evolves over the coming years.”

Groupe RSL produces its diamonds locally in Quebec using a chemical vapour deposition, or CVD, process, whereby hydrogen and methane gas are combined in a plasma under precise conditions to grow diamonds one atom at a time over a period of several weeks to a month. Powered entirely by hydroelectricity, Groupe RSL has developed its own unique process to become the first Canadian company to use this approach to make diamond gems.

“For most of human scientific history, we thought that it was impossible to make diamonds in anything but the hottest high-pressure conditions. That’s why early attempts at man-made diamond focused on replicating the intense pressure that creates diamonds beneath the ground,” adds Sinclair. “Recent research has brought to light a new idea, using hydrogen and methane gas in a controlled reaction.”

Mined diamonds vs. lab-created diamonds
Mined diamonds and lab created diamonds are identical—chemically, physically and optically, and cannot be distinguished from one another without highly specialized equipment. In fact, mined diamonds often contain defects or impurities, both of which can be controlled or removed in lab diamonds.

Consumer shift
There has been a significant increase in demand for lab-grown diamonds in recent years, with lab diamond’s share of diamond sales more than doubling between 2020 and 2022.1 Millennials and Generation Z are moving away from mined diamonds, with nearly 70% of millennials considering buying a lab grown alternative.2 Consumers also seek greater transparency to ensure diamonds are sourced responsibly and produced sustainably. For example, nine in ten Generation Z consumers believe companies have a responsibility to address environmental and social issues.

About Groupe RSL Inc.
Groupe RSL Inc. is an innovative producer of diamond and the only Canadian producer of lab diamonds for the jewellery market. The company produces diamonds using a unique CVD process and technology. Groupe RSL produces beautiful and sustainable Canadian diamonds at its Quebec-based facility which is powered by 100% hydroelectricity. While their diamonds last forever, the company is committed to ensuring their ecological and social footprint does not. For more information, visit www.groupersl.com.

__________________________
1 Diamond industry analyst Edahn Golan. https://www.gemsociety.org/news/2022/05/18/interest-lab-grown-diamonds-surging-shows-no-signs-of-stopping/#:~:text=In%202020%2C%20lab%20diamond's%20share,be%20expected%2C%E2%80%9D%20said%20Golan
2 Millennial Consumer Research Lab Grown Diamonds, MVI Marketing LLC, May 3, 2018.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005008/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release

Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr

IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release

Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye